Jupiter Life Line Hospitals Ltd
JLHLJupiter Life Line Hospitals Ltd is strength at full price. The numbers are improving — and a P/E at the 84th percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 84th percentile of its own range you are paying full price for it.
The price is in a downtrend (28 weeks in) while the P/E sits at the 84th percentile of its own 3-year range. Underneath, the last four quarters read improving — profit +11.1% year on year, and 115% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Jupiter Life Line Hospitals Ltd trades at ₹1,553, in a downtrend and 28 weeks into that stage. That is +14.0% against its own 200-day average. It sits at 91% of a 52-week range of ₹1,212 to ₹1,588. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks.
Today the stock is in a downtrend — week 28 of stage 4. At ₹1,553 it trades +14.0% versus its 200-day average and sits at 91% of its 52-week range (₹1,212–₹1,588).
Against the market, two honest reads. Cumulative: over the last 2.8 years the stock moved +46% while the NIFTY 500 moved +35% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 84th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Jupiter Life Line Hospitals Ltd trades at 55.9× P/E, at the pricey end of its own range (84th percentile). Its long-run median P/E is 50.1×, measured across 2.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 55.9× is at the pricey end of its own range (84th percentile), against a long-run median of 50.1× measured over 2.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +0.5% against a +4.2% price move — the price outran earnings, pushing the multiple UP its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Jupiter Life Line Hospitals Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE slipping at 14.9% — the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +15.2% | +18.9% | +25.3% | — |
| Profit | +0.0% | +38.5% | — | — |
| EPS | +0.5% | +31.9% | — | — |
| Share price | +4.2% | — | — | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
46.7/100 — rank 13 of 19 in Hospitals · 96% evidence confidence
Jupiter Life Line Hospitals Ltd scores 46.7 out of 100 against the 19 companies it is compared with in Hospitals, ranking 13. Price leads the evidence: RS versus the benchmark is 11.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 11.7 + 12.9 + 7 + 15.1 = 46.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Jupiter Life Line Hospitals Ltd reported ₹388 Cr of revenue in the Mar 26 quarter, +15.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 6 years it has compounded at 21.6% a year. The last full year, FY26, came in at ₹1,500 Cr. The last four reported quarters add to ₹1,500 Cr.
Jupiter Life Line Hospitals Ltd reported ₹388 Cr of revenue in the Mar 26 quarter, +15.1% year on year. That is the 12th straight quarter of year-on-year growth. Over 6 years it has compounded at 21.6% a year. The last full year, FY26, came in at ₹1,500 Cr. The last four reported quarters add to ₹1,500 Cr.
FY26 revenue came in at ₹1,500 Cr (+15.2% on the year), capping 6 years at 21.6% compound. The latest quarter (Mar 26) printed ₹388 Cr, +15.1% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +16.1% growth against the decade's 21.6% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +15.9% over the last 4 quarters against +18.4%/yr over the last 8 — stabilising; TTM profit −0.5% vs +4.4%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 23.0% this quarter (−1.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Jupiter Life Line Hospitals Ltd's operating margin is 23.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 7 fiscal years the operating margin has ranged 14.0% to 23.0%. The current quarter sits inside that band.
Jupiter Life Line Hospitals Ltd's operating margin is 23.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 7 fiscal years the operating margin has ranged 14.0% to 23.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 23.0%, −1.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 14.0%–23.0%, and FY26's 23.0% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −0.7 pp year on year while gross margin went +1.0 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins slipped — did that reach the bottom line? Next: profit +11.1% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Jupiter Life Line Hospitals Ltd earned ₹50.0 Cr of net profit in the Mar 26 quarter, +11.1% year on year. Full-year FY26 profit was ₹194 Cr. The 6-year compound rate is 36.5%. That is 12.9% of the quarter's revenue. The same quarter a year earlier earned ₹45.0 Cr.
Jupiter Life Line Hospitals Ltd earned ₹50.0 Cr of net profit in the Mar 26 quarter, +11.1% year on year. Full-year FY26 profit was ₹194 Cr. The 6-year compound rate is 36.5%. That is 12.9% of the quarter's revenue. The same quarter a year earlier earned ₹45.0 Cr.
Mar 26 profit was ₹50.0 Cr, +11.1% year on year. On the full year, FY26 printed ₹194 Cr (+0.0%), and the 6-year compound rate is 36.5%.
Why profit moved: revenue contributed +15.1% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −0.2% vs revenue +16.1%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 115% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 115% of Jupiter Life Line Hospitals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹268 Cr of operating cash against ₹194 Cr of profit. After ₹438 Cr of capital spending, ₹−170 Cr was left as free cash.
FY26: operating cash of ₹268 Cr against reported profit of ₹194 Cr, leaving free cash of ₹−170 Cr after ₹438 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 115% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 115%: the cash cycle stretched 98 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 5.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹951 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Jupiter Life Line Hospitals Ltd's cash conversion cycle runs −54 days in FY26, up from −152 days in FY21. Capital spending ran ₹951 Cr over the last 3 years. At FY26 sales of ₹1,500 Cr each day of that cycle holds about ₹4.1 Cr, so roughly ₹−222 Cr sits inside the business at any moment.
FY26: debtors at 18 days, inventory at 49 days — roughly 1.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −54 days, looser than FY21's −152.
The full loop: cash goes out to suppliers and production on day 0; stock waits 49 days to sell; customers pay about 18 days after that; and suppliers themselves are paid at 121 days — netting out to the −54-day cycle.
In money terms: at FY26 sales of ₹1,500 Cr, each day of the cycle holds about ₹4.1 Cr — so the −54-day loop keeps roughly ₹−222 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹951 Cr over the last 3 fiscal years against ₹187 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹129 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 15% and the ROIC − WACC spread is +1.3 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Jupiter Life Line Hospitals Ltd earns a ROCE of 15% in FY26. That is up from a trough of 7% in FY21. Return on invested capital clears the cost of that capital by +1.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.9% net margin on 0.63× asset turns.
FY26 ROCE is 15%, recovered from a FY21 trough of 7% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 12.9% net margin × 0.63× asset turns × 1.53× balance-sheet leverage ≈ 12.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 13.3% − 12.0% = a +1.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.38.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Jupiter Life Line Hospitals Ltd carries total debt of ₹584 Cr against shareholder equity of ₹1,544 Cr as of Mar 26, a debt-to-equity of 0.38. On the annual view that ratio went from 1.29 in FY23 to 0.38 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹584 Cr against shareholder equity of ₹1,544 Cr — a debt-to-equity of 0.38. On the annual view, debt-to-equity went from 1.29 (FY23) to 0.38 (FY26). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: Foreign institutions added 3.3 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 3.3 points of Jupiter Life Line Hospitals Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 9.4% of the company. Domestic institutions moved +2.7 points over the same window, to 16.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +3.3 points over 8 quarters to 9.4%; Domestic institutions: +2.7 points over 8 quarters to 16.5%; Promoters: +0.0 points over 8 quarters to 40.9%.
Why the register moved: foreign institutions drove it (+3.3 points), alongside domestic institutions (+2.7 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Jupiter Life Line Hospitals Ltd: the Z-score reads 8.37. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 8.37 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 8.37.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Jupiter Life Line Hospitals Ltd this page | 55.9× | ₹10,595 Cr | Mixed | |||
| Apollo Hospitals Enterprise Ltd | 64.7× | ₹1.3L Cr | Consistent | |||
| Max Healthcare Institute Ltd | 70.9× | ₹1.1L Cr | Topping out | |||
| Fortis Healthcare Ltd | 67.8× | ₹71,623 Cr | Mixed | |||
| Aster DM Healthcare Ltd | 168.0× | ₹68,483 Cr | No read | |||
| Narayana Hrudayalaya Ltd | 47.1× | ₹40,085 Cr | Turning around | |||
| Global Health Ltd | 66.2× | ₹36,862 Cr | Consistent | |||
| Krishna Institute of Medical Sciences Ltd | 135.0× | ₹33,510 Cr | Mixed | |||
| Rainbow Childrens Medicare Ltd | 59.8× | ₹14,806 Cr | Mixed | |||
| Healthcare Global Enterprises Ltd | 346.0× | ₹9,952 Cr | Mixed | |||
| Yatharth Hospital & Trauma Care Services Ltd | 46.1× | ₹8,082 Cr | Mixed | |||
| Kovai Medical Center & Hospital Ltd | 26.2× | ₹6,394 Cr | Consistent | |||
| Artemis Medicare Services Ltd | 41.2× | ₹4,365 Cr | Consistent | |||
| Indraprastha Medical Corporation Ltd | 18.2× | ₹3,342 Cr | Mixed | |||
| Dr Agarwals Eye Hospital Ltd | 34.6× | ₹2,427 Cr | Mixed | |||
| KMC Speciality Hospitals (India) Ltd | 45.0× | ₹2,102 Cr | Turning around | |||
| Sakar Healthcare Ltd | 49.5× | ₹1,785 Cr | Improving | |||
| Shalby Ltd | 47.1× | ₹1,762 Cr | Turning around | |||
| KMC Speciality Hospitals (India) Ltd | 37.0× | ₹1,354 Cr | Turning around | |||
| GPT Healthcare Ltd | 30.4× | ₹1,310 Cr | Turning around |
Frequently asked questions
What is Jupiter Life Line Hospitals Ltd's share price today?
Jupiter Life Line Hospitals Ltd trades at ₹1,553, +4.2% over the past year. The company is valued at ₹10,595 Cr. The stock sits at 91% of its 52-week range of ₹1,212–₹1,588, +14.0% versus its 200-day average. On the tape, the price is in a downtrend, 28 weeks in. — as of 24 July 2026.
What were Jupiter Life Line Hospitals Ltd's latest quarterly results?
Jupiter Life Line Hospitals Ltd reported revenue of ₹388 Cr and net profit of ₹50.0 Cr for the Mar 26 quarter. Revenue rose 15.1% and profit rose 11.1% year on year. Earnings per share were ₹1.53. The operating margin was 23.0%, 1.0 pp lower than a year earlier. — as of 24 July 2026.
What is Jupiter Life Line Hospitals Ltd's revenue?
Jupiter Life Line Hospitals Ltd reported revenue of ₹388 Cr in the Mar 26 quarter, +15.1% year on year. For the full FY26 fiscal year, revenue was ₹1,500 Cr (+15.2%). Over the last 6 years revenue compounded at 21.6% a year. — as of 24 July 2026.
What is Jupiter Life Line Hospitals Ltd's profit?
Jupiter Life Line Hospitals Ltd earned ₹50.0 Cr of net profit in the Mar 26 quarter, +11.1% year on year. Full-year FY26 profit was ₹194 Cr. The operating margin ran 23.0% in the latest quarter. — as of 24 July 2026.
What is Jupiter Life Line Hospitals Ltd's market cap?
Jupiter Life Line Hospitals Ltd's market capitalisation is ₹10,595 Cr at a share price of ₹1,553. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Jupiter Life Line Hospitals Ltd's P/E ratio?
Jupiter Life Line Hospitals Ltd trades at a P/E of 55.9×, at the 84th percentile of its own 3-year range, against a long-run median of 50.1×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Jupiter Life Line Hospitals Ltd pay a dividend?
Yes — Jupiter Life Line Hospitals Ltd's dividend payout was 3% of profit in FY26, and it recorded a payout in 3 of its last 7 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Jupiter Life Line Hospitals Ltd overvalued?
On its own history, Jupiter Life Line Hospitals Ltd looks expensive against its own history: its P/E of 55.9× sits at the 84th percentile of its 3-year range (long-run median 50.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Jupiter Life Line Hospitals Ltd growing?
Yes — Jupiter Life Line Hospitals Ltd is growing: latest-quarter revenue +15.1% year on year, profit +11.1%, and the margin −1.0 pp at 23.0%. The 6-year compound rates are 21.6% (revenue) and 36.5% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Jupiter Life Line Hospitals Ltd performing?
Jupiter Life Line Hospitals Ltd is in a downtrend, 28 weeks in. Its latest quarter's revenue rose 15.1% and profit rose 11.1% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Jupiter Life Line Hospitals Ltd in?
Mixed — no clean majority across the growth curves, ROCE slipping at 14.9% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +15.9% latest, profit growth −0.5% latest, eps growth +0.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Jupiter Life Line Hospitals Ltd in an uptrend?
No — the price is in a downtrend (week 28 of stage 4), trading +14.0% versus its 200-day average and at 91% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Jupiter Life Line Hospitals Ltd beating the market?
On recent form, yes — Jupiter Life Line Hospitals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.8 years the stock moved +46% against the NIFTY 500's +35% — ahead of the index over the full window. — as of 24 July 2026.
Will Jupiter Life Line Hospitals Ltd's share price go up?
This page publishes no price forecast for Jupiter Life Line Hospitals Ltd. What it measures instead: the share price is ₹1,553, the price is in a downtrend 28 weeks in. Its P/E of 55.9× sits at the 84th percentile of its own 3-year range. — as of 24 July 2026.
Who owns Jupiter Life Line Hospitals Ltd?
Promoters hold 40.9% of Jupiter Life Line Hospitals Ltd, foreign institutions 9.4%, domestic institutions 16.5% and the public 33.2% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 3.3 points over 8 quarters. — as of 24 July 2026.
Does Jupiter Life Line Hospitals Ltd have too much debt?
It is moderate — Jupiter Life Line Hospitals Ltd's debt-to-equity is 0.38, and operating profit covers the interest bill 10×. FY26 borrowings were ₹584 Cr against equity of ₹1,545 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Jupiter Life Line Hospitals Ltd's capex?
Jupiter Life Line Hospitals Ltd spent ₹951 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹438 Cr, with ₹129 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Jupiter Life Line Hospitals Ltd's cash flow?
Jupiter Life Line Hospitals Ltd generated ₹268 Cr of operating cash flow in FY26 and ₹−170 Cr of free cash flow after ₹438 Cr of capital spending. Reported profit that year was ₹194 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Jupiter Life Line Hospitals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 115% of Jupiter Life Line Hospitals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹268 Cr against reported profit of ₹194 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Jupiter Life Line Hospitals Ltd?
On the balance sheet, the Z-score reads 8.37 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Jupiter Life Line Hospitals Ltd in its business cycle?
Jupiter Life Line Hospitals Ltd's FY26 operating margin was 23.0%, against a 7-year band of 14.0%–23.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 23.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Jupiter Life Line Hospitals Ltd story?
The sharpest disagreement: the engine is strong, but at the 84th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Jupiter Life Line Hospitals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Jupiter Life Line Hospitals Ltd is strength at full price. The numbers are improving — and a P/E at the 84th percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.